0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Clinical Evaluation of Cephaloridine

Neal H. Steigbigel, MD; Jay Ward Kislak, MD; Jeremiah G. Tilles, MD; Maxwell Finland, MD
Arch Intern Med. 1968;121(1):24-38. doi:10.1001/archinte.1968.03640010026004.
Text Size: A A A
Published online

Cephaloridine was used to treat 136 bacterial infections in 122 hospitalized patients. Its antibacterial and clinical effectiveness against serious staphylococcal infections compared favorably with that of cephalothin sodium and of penicillinase-resistant penicillins in similar cases. Cephaloridine was highly effective clinically and in eradicating the causative organisms in infections due to pneumococci, streptococci, Escherichia coli, and Proteus mirabilis; but its effectiveness against klebsielleae was variable. Superinfection with resistant gram-negative bacilli and serious noninfectious conditions were the major causes of most of the deaths. Injections of cephaloridine were remarkably well tolerated. Cross sensitization with penicillin was not encountered. Cephaloridine may have caused or contributed to acute renal failure and to an unusual coagulopathy, each observed in two patients. Cephaloridine is a highly effective and useful antibacterial agent when selected and used with due regard to its activity and potential nephrotoxicity.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();